Clinical trials: Influenza, completed
Flu, Human, Influenza, Human
Persuasion in Medicine: Experimental Evidence on Sender and Signal Effects
The aim of the study is to identify what sender/signal combinations are most persuasive in encouraging low socioeconomic males living in the U.S. to take-up seasonal flu vaccination.
- Conditions
- Flu, Human, Influenza, Human, Covid19
- Trial name
- NCT04160975
- Testing
- Video about safety and effectiveness of adult seasonal flu vaccination
- Where
- United States
- Volunteers
- 3,245 people, healthy volunteers welcome
- Sponsor
- Harvard University
Influenza
Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults
The purpose of this study is to examine the safety and tolerability after administration of trivalent and quadrivalent cell-based virosomal influenza vaccine in healthy adults.
- Trial name
- NCT02148328
- Testing
- Trivalent virosomal influenza vaccine, Commercial vaccine 1, Quadrivalent virosomal influenza vaccine
- Where
- 4 sites in Belgium
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Seasonal Influenza
Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (7.5μg/0.25ml)
The purpose of this study is to evaluate the safety and immunogenicity of quadrivalent influenza vaccine in healthy children aged 6-35 months.
- Trial name
- NCT03859141
- Testing
- Quadrivalent influenza vaccine, Trivalent influenza vaccine (contains B/Victoria strain), Trivalent influenza vaccine (contains B/Yamagata strain)
- Where
- 2 sites in China
- Volunteers
- 2,340 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Virus Diseases, RNA Virus Infections
Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults
This Phase 2 Quadrivalent VLP Vaccine study is intended to replicate and extend the immunogenicity and safety results obtained in earlier Phase 1-2 and Phase 2 studies.
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT02831751
- Testing
- 30 µg/strain of Quadrivalent VLP Vaccine, 60 µg/strain of Quadrivalent VLP Vaccine, FluLaval® Tetra (15 µg/strain)
- Where
- 15 sites in United States, Canada
- Volunteers
- 1,001 people, healthy volunteers welcome
- Sponsor
- Medicago
H7N9 Influenza
Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years
Evaluate the safety and immunogenicity of four different doses of H7N9 vaccination in adults between the ages of 18 years and 65 years.
- Trial name
- NCT01928472
- Testing
- H7N9c low dose with adjuvant, H7N9c medium dose with adjuvant, H7N9c high dose with adjuvant
- Where
- 6 sites in United States
- Volunteers
- 402 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
A Study to Assess the Safety and Immunogenicity of a New Influenza Vaccine Candidate MVA-NP+M1 in Healthy Adults
This is an open label phase I study, to assess the safety of a novel influenza vaccine, MVA-NP+M1. All volunteers recruited will be healthy.
- Trial name
- NCT00942071
- Testing
- MVA-NP+M1
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Influenza
Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents
This is a Phase I, dose escalation study in healthy adolescents and children (6-17 years) to evaluate the safety, tolerability, and immunogenicity of a prime-boost regimen of the 2012/2013 seasonal influenza DNA vaccine (HA DNA)…
- Trial name
- NCT01609998
- Testing
- Seasonal Influenza DNA vaccine, TIV
- Where
- 5 sites in United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Influenza Vaccines
Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population
Influenza pandemics are caused by viruses that possess an Hemagglutinin molecule to which most of the population lacks immunity.
- Trial name
- NCT00306995
- Testing
- SB218352_15, SB218352_8, SB218352_4
- Where
- 10 sites in Germany
- Volunteers
- 385 people
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity and Safety of Fluzone® Quadrivalent, Southern Hemisphere 2015 Formulation (Intramuscular Route)
The aim of the study was to assess the immunogenicity and safety of Fluzone Quadrivalent influenza vaccine Southern Hemisphere (SH) 2015 formulation in participants aged 18 to 60 years as well as in participants 61 years or…
- Trial name
- NCT03546192
- Testing
- Fluzone Quadrivalent Influenza Vaccine
- Where
- 3 sites in Philippines
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Human
A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years
This is a study to assess the safety of a bioCSL split virion, inactivated Trivalent Influenza Virus vaccine containing the 2014/2015 Northern Hemisphere strains of vaccine in children aged 5 years to less than 9 years.
- Trial name
- NCT02212106
- Testing
- bioCSL Trivalent Influenza Virus Vaccine (CSL TIV), Comparator Quadrivalent Influenza Virus Vaccine
- Where
- 11 sites in United States
- Volunteers
- 402 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza Immunization
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of up to 3 dose levels of Quadrivalent Influenza mRNA Vaccine MRT5410 compared to an active control (QIV SD, QIV HD…
- Trial name
- NCT05624606
- Testing
- Quadrivalent Influenza mRNA Vaccine MRT5410, Quadrivalent Recombinant Influenza vaccine RIV4, Quadrivalent Inactivated Influenza Standard Dose QIV-SD
- Where
- 25 sites in United States, Puerto Rico
- Volunteers
- 682 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza A Virus Infection, Influenza A
The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac
The present clinical phase I study designed to examine the safety, reactogenicity and immunogenicity of the medicinal product - Vaccine vector against influenza A - in healthy volunteers after a single dose in the three groups…
- Conditions
- Influenza A Virus Infection, Influenza A, Influenza Epidemic, Influenza H5N1
- Trial name
- NCT03651544
- Testing
- GamFluVac
- Where
- Russia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Influenza
H5 Vaccine Alone or With Aluminum Hydroxide in Elderly Adults
The purpose of this study is to compare how the body reacts to different strengths of the new A/H5N1 flu vaccine when given with the addition of aluminum hydroxide adjuvant and provide dosing information.
- Trial name
- NCT00294099
- Testing
- Aluminum hydroxide, Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)
- Where
- 7 sites in United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy
A Prospective Study to Evaluate the Safety of a New Monovalent Intranasal Influenza Vaccine
This prospective annual release study was designed to assess the safety of a monovalent influenza virus vaccine using a new strain recommended for the 2009-2010 influenza season not previously contained in the trivalent…
- Trial name
- MI-MA205 (NCT00873912)
- Testing
- Monovalent influenza virus vaccine
- Where
- 3 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Healthy
Training Study to Characterize Biomarkers to Flu Vaccines
It is thought that vaccines trigger innate inflammatory responses to induce antigen-specific adaptive immunity (the desired effect), but excessive inflammation may lead to serious inflammatory complications or unwanted side…
- Trial name
- NCT01771367
- Testing
- Fluad, Agrippal
- Where
- United Kingdom
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- University of Surrey
Influenza
Safety and Protective Efficacy of FF-3 Dry Powder in Healthy Subjects Infected With Influenza Challenge Strain
The purpose of this study are to determine the effect FF-3 in comparison to placebo in subjects who are experimentally inoculated with a live, challenge strain of influenza A virus.
- Trial name
- NCT02423577
- Testing
- FF-3 dry powder
- Where
- United Kingdom
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Autoimmune Technologies, LLC
Influenza
Live Attenuated Influenza Vaccine as a Nasal Model for Influenza Infection
The purpose of this study is to develop a nasal model for influenza infection using the live attenuated influenza vaccine (LAIV).
- Trial name
- NCT04164212
- Testing
- Flumist Quadrivalent Nasal Product
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Seasonal Influenza
Safety and Immunogenicity of an A (H1N1) 2009 Influenza Virus-like Particle (VLP) Vaccine
This is a Phase 2 randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and immunogenicity of three dose levels (5µg, 15µg and 45µg HA) of the novel A (H1N1) influenza VLP vaccine as compared…
- Trial name
- NCT01072799
- Testing
- A/H1N1 2009 Influenza VLP Vaccine
- Where
- Mexico
- Volunteers
- 4,560 people, healthy volunteers welcome
- Sponsor
- Novavax
COVID-19, Influenza
A Study of the GRIP Influenza and SARS-CoV-2 POC Assays
The purpose of this research is to determine if the use of a new device can accurately detect a virus infection.
- Trial name
- NCT05674370
- Testing
- GRIP Electronic Diagnostic Chip, Laboratory-based nucleic acid amplification tests (NAATs)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Mayo Clinic
Influenza
Pooled Analysis of Methodologically Harmonized Pragmatic Randomized Trials of High-Dose vs. Standard-Dose Influenza Vaccine Against Severe Clinical Outcomes
This prespecified analysis will pool the datasets from two pragmatic randomized trials evaluating the relative vaccine effectiveness of high-dose vs.
- Trial name
- FLUNITY-HD (NCT06506812)
- Testing
- High-Dose Influenza Vaccine, Standard-Dose Influenza Vaccine
- Where
- Denmark
- Volunteers
- 466,320 people
- Sponsor
- Tor Biering-Sørensen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.